Jou(RNA)l – CureVac’s Newsroom

This section contains the latest press releases and media reports about CureVac.

  • University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator
    18-11-07 / Press Release
    Read more
  • CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the 2018 Society for Immunotherapy of Cancer Annual Meeting
    18-11-07 / Press Release
    Read more
  • CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA
    18-10-23 / Press Release
    Read more
  • CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations
    18-06-12 / Press Release
    Read more
  • CureVac Announces New Management Structure
    18-05-08 / Press Release
    Read more
  • CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA
    18-03-22 / Press Release
    Read more
  • CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria
    18-02-13 / Press Release
    Read more
  • CureVac Expands Intellectual Property Position that Significantly Improves Protein Expression for its mRNA-Based Vaccines and Therapeutics
    18-01-24 / Press Release
    Read more
  • CureVac Highlights Key 2018 Corporate Milestones and Outlook
    18-01-10 / Press Release
    Read more
  • Fortune:"Bill Gates Just Delivered a Powerful Message to the Drug Industry"
    18-01-09 / Media Report
    Read more
  • CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics
    18-01-04 / Press Release
    Read more
  • CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs
    17-11-13 / Press Release
    Read more
  • 5th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration
    17-11-06 / Press Release
    Read more
  • CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics
    17-10-29 / Press Release
    Read more
  • CureVac Initiates Phase I Clinical Trial of RNAdjuvant® Candidate as Intratumoral Therapy for Solid Tumors
    17-10-27 / Press Release
    Read more
  • Publication in npj Vaccines Demonstrates CureVac’s RNActive® Vaccine is Superior to Licensed Vaccines
    17-10-23 / Press Release
    Read more
  • Endpoints News: "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines"
    17-10-20 / Media Report
    Read more
  • FierceBiotech: "Lilly, CureVac pen $1.8B mRNA cancer vaccine deal"
    17-10-18 / Media Report
    Read more
  • Financial Times: "Eli Lilly invests in Germany’s CureVac in cancer vaccine drive"
    17-10-18 / Media Report
    Read more
  • Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
    17-10-18 / Press Release
    Read more
  • Nature Biotechnology: "A successful founder off the beaten path"
    17-10-12 / Media Report
    Read more
  • BIOspektrum: "Molekulare Medizin - mRNA-basierte Therapien für eine passive Immunisierung"
    17-09-11 / Media Report
    Read more
  • Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors
    17-08-15 / Press Release
    Read more
  • 5th International mRNA Health Conference to Showcase Tremendous Advances in the Development of mRNA Drugs
    17-07-31 / Press Release
    Read more
  • Handelsblatt Global: "Vaccine research - Rabid about Curevac"
    17-07-27 / Media Report
    Read more
  • CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine
    17-07-26 / Press Release
    Read more
  • CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies
    17-07-20 / Press Release
    Read more
  • CureVac Expands GMP Production Capacities for RNA Products
    17-06-26 / Press Release
    Read more
  • CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines
    17-06-13 / Press Release
    Read more
  • CureVac to Present at Upcoming International Investor Conferences
    17-05-19 / Press Release
    Read more
  • CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary
    17-05-02 / Press Release
    Read more
  • Handelsblatt Global: "Top Innovators - Germany's Quiet Visionaries, Part X"
    17-03-17 / Media Report
    Read more
  • Nature Biotechnology: "The 'anti-hype' vaccine"
    17-02-27 / Media Report
    Read more
  • BioCentury: "mRNA test kitchens - Where biopharma is betting on mRNA"
    17-02-25 / Media Report
    Read more
  • European Biotechnology: "Biotech CEOs advise EU on breakthrough innovations"
    17-01-23 / Media Report
    Read more
  • CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group
    17-01-20 / Press Release
    Read more
  • Handelsblatt Global Edition: "Bill Gates: We Need To Be Prepared For Epidemics"
    17-01-19 / Media Report
    Read more
  • idw - Informationsdienst Wissenschaft (German): "Bill Gates: We Need To Be Prepared For Epidemics"
    17-01-17 / Media Report
    Read more
  • CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference
    17-01-11 / Press Release
    Read more
  • CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017
    16-12-28 / Press Release
    Read more
  • Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma (HCC) Patients and Healthy Subjects to the RNA-based adjuvant
    16-12-05 / Press Release
    Read more
  • CureVac Secures an Additional $29.5 Million From Two New Investors
    16-11-08 / Press Release
    Read more
  • CureVac Receives Broad Patent for RNAntibody® Technology
    16-11-08 / Press Release
    Read more
  • GEN (Genetic Engineering & Biotechnology News): "Enabling the Body to Manufacture Its Own Medicine"
    16-11-02 / Media Report
    Read more
  • CureVac Appoints Pierre Kemula as Chief Financial Officer
    16-10-11 / Press Release
    Read more
  • Deutsches Ärzteblatt (German): "HIV-Impfung: Nicht in Sicht, aber in Arbeit"
    16-08-08 / Media Report
    Read more
  • Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines
    16-07-14 / Press Release
    Read more
  • The Wall Street Journal: "Ebola, Zika Push Global Health Leaders on Disease Fight, Bill & Melinda Gates Foundation CEO Says"
    16-05-23 / Media Report
    Read more
  • Handelsblatt (German): "Deutschland braucht mehr Erfolgsstorys"
    16-04-13 / Media Report
    Read more
  • Süddeutsche Zeitung (German): "Das Geschäft machen andere"
    16-04-13 / Media Report
    Read more
  • Stuttgarter Zeitung (German): "Deutsche Biotech-Branche schöpft Potenzial nicht aus"
    16-04-12 / Media Report
    Read more
  • CureVac Appoints Leading Experts to its Scientific Advisory Board
    16-03-30 / Press Release
    Read more
  • DER SPIEGEL (German): "Einhorn aus Tübingen - Curevac gilt als größte Hoffnung der deutschen Biotech-Szene..."
    16-03-26 / Media Report
    Read more
  • CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion
    16-03-18 / Press Release
    Read more
  • CureVac announces “MERAN” has been approved by the World Health Organization as suffix for mRNA drug substances
    16-02-18 / Press Release
    Read more
  • CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference
    16-01-06 / Press Release
    Read more
  • LaBiotech: "Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?"
    16-01-05 / Media Report
    Read more
  • Handelsblatt (German): "Es geht uns nicht ums Geldverdienen"
    15-12-16 / Media Report
    Read more
  • Frankfurter Allgemeine Zeitung (German): "Nur mal schnell die Welt retten"
    15-12-13 / Media Report
    Read more
  • Rhein-Neckar-Zeitung (German): "Mannheim: Roche offen für Partnerschaften"
    15-11-13 / Media Report
    Read more
  • CureVac raises $110 Million in a private placement
    15-11-03 / Press Release
    Read more
  • Handelsblatt (German): "Curevac erhält Finanzspritze - 100 Millionen Euro für den Biotech-Star"
    15-11-03 / Media Report
    Read more
  • DowJones VENTUREWIRE: "CureVac Amasses $110M for Messenger RNA Therapeutics"
    15-11-03 / Media Report
    Read more
  • FierceBiotech: "Gates, Hopp back $110M megaround for CureVac's mRNA work"
    15-11-02 / Media Report
    Read more
  • Xconomy: "CureVac Opens up an mRNA Hub in Moderna’s Cambridge Backyard"
    15-09-10 / Media Report
    Read more
  • IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates
    15-09-10 / Press Release / News
    Read more
  • CureVac Establishes U.S. Operations in Cambridge, MA
    15-09-10 / Press Release / News
    Read more
  • Süddeutsche Zeitung (German): "Pioniere der Biotechnologie"
    15-09-02 / Media Report
    Read more
  • Frankfurter Allgemeine Sonntagszeitung / faz.net (German): "Milliarden für ein Molekül"
    15-08-30 / Media Report
    Read more
  • CureVac & Bill & Melinda Gates Foundation - Collaboration to Develop mRNA Vaccines Expands
    15-08-04 / Press Release / News
    Read more
  • BIOPRO (German): "CureVac und Boehringer Ingelheim - zwei starke Partner im Kampf gegen Krebs"
    15-07-13 / Media Report
    Read more
  • CureVac Announces Phase I/IIa Clinical Study Data
    15-07-07 / Press Release / News
    Read more
  • CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs
    15-06-24 / Press Release
    Read more
  • The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology
    15-03-05 / Press Release / News
    Read more

Your contact

Matthew Beck
Vice President Investor Relations
T: +1 917 415 1750
contact via e-mail

CureVac's Scientific Publications

can be found here...